Brodalumab
Siliq, Kyntheum (brodalumab) is an antibody pharmaceutical. Brodalumab was first approved as Siliq on 2017-02-15. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. It is known to target interleukin-17 receptor A.
| Trade Name | Kyntheum |
|---|---|
| Common Name | Brodalumab |
| Indication | psoriasis |
| Drug Class | Monoclonal antibodies: fully human, immunomodulating |
